NIAID TESTS GREFFEX’S AVIAN FLU (H5N1) VACCINE

January 9, 2015

In studies sponsored by the National Institute of Allergy and Infectious Disease (NIAID), Greffex’s GreFluVie vaccine proved to be highly effective in protecting animals against H5N1. Mice were immunized in a prime/boost schedule before being challenged with a lethal dose of the pandemic avian influenza virus. At the low dose of 3×108 genome equivalents, the vaccine proved to be highly effective when given by intramuscular, subcutaneous, and intranasal routes. Intramuscular injection resulted in a rate of survival of 100%.

Comments are closed.